ロード中...
Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
PURPOSE: Cancer cachexia is characterized by decreased body weight (mainly lean body mass [LBM]) and negatively impacts quality of life (QOL) and prognosis. Anamorelin (ONO-7643) is a novel selective ghrelin receptor agonist under development for treating cancer cachexia. METHODS: In this double-bli...
保存先:
| 出版年: | Support Care Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2016
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4917578/ https://ncbi.nlm.nih.gov/pubmed/27005463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-016-3144-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|